Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants

Genetics in Medicine(2021)10.1016/j.gim.2021.08.016Source: DataRank Database

Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants is a research paper published in Genetics in Medicine (2021). On theSindex it has a DataRank of 1.2. It has been cited 31 times, with 20 citing works in its 1-hop citation network.

N/A

1.2DataRank · unranked

Scored on demand from live citation data

Open Access31 citations · 20 citing works in its network

Download PDF

Cite:

Linked data & code

omim

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (32 grants)OA: bronzeTopics (33)IDs (PubMed, PMC)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 43%Citation Network 57%

Base Score Contribution

0.520

From this paper's citation signal

Citation Network Contribution

0.686

From 18 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 20 citers.

Ovarian cancer onset across different BRCA mutation types: a view to a more tailored approach for BRCA mutated patients
International Journal of Gynecological Cancer202214 citations29 referencesContributes 0.093
How the Analysis of the Pathogenetic Variants of DDR Genes Will Change the Management of Prostate Cancer Patients
International Journal of Molecular Sciences20228 citations31 referencesContributes 0.071
Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD—Long-term Survival of the GeparOLA Study
Clinical Cancer Research20255 citations27 referencesContributes 0.066
Immunohistochemical Detection of the Expressed BRCA1 and BRCA2 Proteins in Microenvironment of Malignant Breast Cancerous Tissues Infected with Human Mammary Tumor Virus
Asian Pacific Journal of Cancer Prevention20232 citations17 referencesContributes 0.065
Prognostic impact of germline BRCA1/2 pathogenic variants in breast cancer
Breast Cancer Research and Treatment20224 citations26 referencesContributes 0.062

Authors (61)

Christoph Engel ORCID,Miguel de la Hoya ORCID,Paolo Peterlongo ORCID,Drakoulis Yannoukakos ORCID,Luca Livraghi ORCID

Live enrichment

PubMed:34906479 PMC:PMC10170303

Associazione Italiana per la Ricerca sul Cancro

Grant: IG-16732

Associazione Italiana per la Ricerca sul Cancro

Grant: 22093

Financiadora de Estudos e Projetos

Grant: 02/2010

National Health and Medical Research Council

Grant: ID1177524

Cancer Research UK

Grant: C12292/A20861

Cancer Research UK

Grant: PPRPGM-Nov20/100002

National Cancer Institute

Grant: R01 CA116167

National Cancer Institute

Grant: P50 CA116201

National Cancer Institute

Grant: R35 CA253187

National Cancer Institute

Grant: R01 CA225662

Instituto de Salud Carlos III

Grant: INT15/00070

Instituto de Salud Carlos III

Grant: INT20/00071

Instituto de Salud Carlos III

Grant: INT16/00154

Instituto de Salud Carlos III

Grant: INT17/00133

NCI NIH HHS

Grant: UM1 CA164920

NCI NIH HHS

Grant: R01 CA192393

Cancer Research UK

Grant: 20861

Cancer Research UK

Grant: PPRPGM-Nov20\100002

Institut National du Cancer

Grant: unidentified

unidentified

National Institutes of Health

Grant: 5UM1CA164920-03

Breast Cancer Family Registry Cohort

National Institutes of Health

Grant: 1R01CA116167-01A1

BRCA2 missense mutations and breast cancer

National Institutes of Health

Grant: 5R01CA225662-05

The contribution of RAD51C and RAD51D to breast and ovarian cancer

National Institutes of Health

Grant: 5R35CA253187-06

Resolving the cancer relevance of predisposition gene mutations

National Institutes of Health

Grant: 5P50CA116201-08

Career Development (Ingle)

National Institutes of Health

Hospital de Câncer de Barretos

European Commission

Conselho Nacional de Desenvolvimento Científico e Tecnológico

European Regional Development Fund

Breast Cancer Research Foundation

Ministerio de Ciencia e Innovación

Fundación Mutua Madrileña

bronzeLicense: Elsevier Non-Commercial

publisherhttp://www.gimjournal.org/article/S1098360021011308/pdf

publisherhttps://api.elsevier.com/content/article/PII:S1098360021011308?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1098360021011308?httpAccept=text/plain

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10170303

repositoryhttp://hdl.handle.net/1887/3563134

Fields of Study

0301 basic medicine0303 health sciences03 medical and health sciences

MeSH Terms

HumansBreast NeoplasmsOvarian NeoplasmsGenetic Predisposition to DiseaseBRCA1 ProteinBRCA2 ProteinGerm-Line MutationGenes, BRCA1Genes, BRCA2Middle AgedFemaleGenetic Testing

Keywords

BRCA1BRCA2Missense VariantsCancer RisksBRCA2 ProteinOvarian NeoplasmsBRCA1 ProteinGenes, BRCA2Genes, BRCA1610Breast NeoplasmsMiddle AgedBRCA1; BRCA2; Cancer risks; Missense variants;HumansFemaleGenetic Predisposition to DiseaseGenetic TestingGerm-Line Mutation

Sustainable Development Goals

SDG 3: 3. Good health